Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenocarcinoma of the Pancreas Clear all
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

NCT00201838
View directory record Official record
Conditions
Pancreatic Neoplasms, Adenocarcinoma
Interventions
Gemcitabine, Etanercept
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Jul 21, 2026, 5:58 PM EDT
Not listed Not applicable Interventional

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT00079365
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, brachytherapy, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 21, 2026, 5:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

NCT07148128
View directory record Official record
Conditions
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Interventions
WEF-001
Drug
Lead sponsor
Auricula Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Early Phase 1 Interventional

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

NCT01821612
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 3 Interventional

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00058149
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Aurora, Colorado + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01280058
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Early Phase 1 Interventional

Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer

NCT02153450
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer
Interventions
metformin hydrochloride, stereotactic radiosurgery
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jul 21, 2026, 5:58 PM EDT
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03697239
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions
Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hitendra Patel
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397
View directory record Official record
Conditions
Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
Interventions
CC-223
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

NCT02030860
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Paricalcitol, Abraxane, Gemcitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

NCT00028834
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jul 21, 2026, 5:58 PM EDT
Recruiting Not applicable Interventional

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

NCT05053555
View directory record Official record
Conditions
Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
Interventions
high dose rate brachytherapy
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 5:58 PM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

NCT00836992
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Jul 21, 2026, 5:58 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT00326911
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
cetuximab, bevacizumab, gemcitabine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • San Francisco, California • Stamford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00288093
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7
Interventions
3-Dimensional Conformal Radiation Therapy, Triapine
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00005832
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
R115777
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
14
States / cities
Los Angeles, California • Martinez, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 21, 2026, 5:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Interventions
Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

NCT00100815
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, capecitabine, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Jul 21, 2026, 5:58 PM EDT
Completed No phase listed Observational

Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice

NCT02277834
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

NCT00091026
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
cetuximab, gemcitabine hydrochloride, bevacizumab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 21, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

NCT00769483
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
MK-0646, Gemcitabine, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Jul 21, 2026, 5:58 PM EDT
Active, not recruiting No phase listed Observational

Predicting Effective Therapy in Pancreatic Cancer

NCT03033927
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
CTC isolocation and analysis
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 21, 2026, 5:58 PM EDT
Terminated Phase 1 Interventional

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

NCT01025570
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Bosutinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 21, 2026, 5:58 PM EDT